Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target

(E-pub Ahead of Print)

Author(s): Claudia Ferroni*, Greta Varchi*.

Journal Name: Current Medicinal Chemistry

Become EABM
Become Reviewer

Abstract:

The androgen receptor (AR) pathway plays a major role in both the pathogenesis and progression of prostate cancer. In particular, AR is chiefly involved in the development of castration-resistant prostate cancer (CRPC) as well as in the resistance to the secondgeneration AR antagonist enzalutamide, and to the selective inhibitor of cytochrome P450 17A1 (CYP17A1) abiraterone. Several small molecules acting as AR antagonists have been designed and developed so far, also as a result of the ability of cells expressing this molecular target to rapidly develop resistance and turn pure receptor antagonists into ineffective or event detrimental molecules. This review covers a survey of most promising classes of non-steroidal androgen receptor antagonists, also providing insights into their mechanism of action and efficacy in treating prostate cancer.

Keywords: androgen receptor, castration resistant prostate cancer, antiandrogens, point mutations, PROTACs, AR protein degraders, AR-targeting conjugates.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867325666180913095239
Price: $95

Article Metrics

PDF: 12